logo.jpg
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle
December 20, 2021 23:30 ET | Sanofi - Aventis Groupe
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle Une opération qui apporte un portefeuille...
logo.jpg
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
December 20, 2021 23:30 ET | Sanofi - Aventis Groupe
 Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics Adds promising pipeline of T-cell engagers and cytokine therapies with lead candidate...
amunix logo (high res no tag).png
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 09:00 ET | Amunix Pharmaceuticals, Inc.
AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment...
amunix logo (high res no tag).png
Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
June 23, 2021 07:00 ET | Amunix Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN...
amunix logo (high res no tag).png
Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors
January 26, 2021 07:00 ET | Amunix Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
amunix logo (high res no tag).png
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
September 17, 2020 07:00 ET | Amunix Pharmaceuticals, Inc.
– Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors –       –     Masked prodrug...
amunix logo (high res no tag).png
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
June 22, 2020 09:00 ET | Amunix Pharmaceuticals, Inc.
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid...
amunix logo (high res no tag).png
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality
May 27, 2020 07:00 ET | Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
amunix logo (high res no tag).png
Amunix Raises $73 Million in Series A Financing Led by Omega Funds
March 04, 2020 07:00 ET | Amunix Pharmaceuticals, Inc.
-- Harnessing clinically validated prodrug technology to advance novel pipeline of T cell engager and cytokine agents that are selectively activated in the tumor microenvironment --  -- Proprietary T...
amunix logo.jpg
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer
August 27, 2019 07:03 ET | Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...